Cardiome anticipates that other directors, officers and employees of the Corporation will adopt automatic securities disposition or purchase plans. Insiders of Cardiome that adopt a plan will disclose the establishment of the plan in insider reports filed in accordance with applicable Canadian securities laws and Cardiome may from time to time disclose the adoption of such plans in the future.
About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a product-focused drug development company dedicated to the advancement and commercialization of novel treatments for disorders of the heart and circulatory system. Cardiome is traded on the NASDAQ Global Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.
Forward-Looking Statement Disclaimer
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unkn
'/>"/>
| SOURCE Cardiome Pharma Corp. Copyright©2009 PR Newswire. All rights reserved |